The Novartis Access one-year report describes first results, early learnings and challenges from our first twelve months on the ground. It also includes external perspectives and country updates, showcasing the progress we have made as we roll out the program.

Since 2015, Novartis Access has worked to deliver treatments for chronic diseases in lower-income countries. Read our two-year report for an in-depth look at results, learnings and challenges on the ground so far. It includes external perspectives and country updates, showcasing the progress we have made as we roll out the program.

As a leading healthcare company, we have a responsibility to help people get access to the treatments they need, no matter where they live. Our CR Performance Report gives you all the facts on the progress we are making. It is issued at the same time as our Annual Report to provide readers with a more integrated view of Novartis.

10 years ago we launched the Healthy Family program, Novartis first social business model, to improve health via education, affordable products and health services. This report provides information on how the program has evolved since then. It includes external perspectives and country updates, showcasing the learnings and progress we have made over the years.

The Annual Report provides an overview of our strategy and reviews the performance of Novartis in 2017.

Our Annual Report 2018 provides a comprehensive overview of Novartis, including our corporate governance, compensation practices, and operating and financial results.

MalaFA (Malaria Futures for Africa) is an opinion research study commissioned by Novartis to capture the views of African malaria experts in 15 sub-Saharan African countries – from government, the research community and NGOs – on progress and remaining challenges toward the 2030 global malaria goals. Study co-chairs are Dr Richard Kamwi, Ambassador, Elimination 8 (E8), and Professor Bob Snow, of the KEMRI-Wellcome Trust programme, Kenya and University of Oxford, United Kingdom.

Transparent reporting has been a central part of our CR commitment for many years, and we continue to make progress in this area. Our Novartis in Society Report (formerly the Corporate Responsibility Report) is issued at the same time as our Annual Report to provide readers with a more integrated view of Novartis.

Our stakeholders have important questions about our business practices in the United States, including our approach to price adjustments, patient assistance, investment in research and development, and marketing. The Novartis in Society US report aims to help answer those questions.

Novartis Social Business (NSB) brings together the company’s key access-to-healthcare programs, including the Novartis Malaria Initiative, SMS for Life, Novartis Healthy Family, and Novartis Access. The 2018 NSB report provides a comprehensive overview of recent activities, and shows how these helps lower-income countries manage the dual burden of infectious and chronic diseases.

MalaFA (Malaria Futures for Asia) is an opinion research study commissioned by Novartis to capture the views of malaria experts in five countries in South and Southeast Asia – from government, the research community and NGOs – on progress and remaining challenges toward the 2030 malaria elimination goals. Study co-chairs are HE Yongyuth Yuthavong, former Deputy Prime Minister of Thailand and a member of the RBM Partnership to End Malaria board, and Dr Srinath Reddy, President of the Public Health Foundation of India.

Transparent reporting has been a central part of our CR commitment for many years, and we continue to make progress in this area. Our Novartis in Society Report is issued at the same time as our Annual Report to provide readers with a more integrated view of Novartis.